SCHEMBL2370530

SCHEMBL2370530

COC(=O)Cc1ccc(N2CCN(C)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.60
MAPT P10636 4/20 0.59
ALDH1A1 P00352 2/20 0.59
LMNA P02545 2/20 0.58
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
CHKA P35790 1/20 0.53
HDAC3 O15379 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
NCF1 P14598 1/20 0.50
CYP4F2 P78329 1/20 0.50
CYP4A11 Q02928 1/20 0.50
GAA P10253 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
KMT2A Q03164 1/20 0.49
GFER P55789 1/20 0.49
LIPE Q05469 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261694 0.87 MAPT (0.61) SMN1; SMN2MAPTALDH1A1LMNANPC1
SCHEMBL20425234 0.85 SMN1; SMN2 (0.62) SMN1; SMN2MAPTALDH1A1LMNAGAA
SCHEMBL21624879 0.85 MAPT (0.55) SMN1; SMN2MAPTALDH1A1LMNANPC1
SCHEMBL2650247 0.84 MAPT (0.78) SMN1; SMN2MAPTALDH1A1LMNARAB9A
SCHEMBL10899752 0.83 ALDH1A1 (0.57) SMN1; SMN2MAPTALDH1A1LMNACYP4F2
SCHEMBL29589898 0.82 AGXT (0.58) SMN1; SMN2MAPTALDH1A1LMNANPC1
SCHEMBL15710135 0.82 AGXT (0.58) SMN1; SMN2MAPTALDH1A1LMNANPC1
SCHEMBL2371447 0.82 ITGB3 (0.63) SMN1; SMN2MAPTALDH1A1LMNANPC1
Hydrochloric Acid SCHEMBL7366386 0.82 ALDH1A1 (0.56) SMN1; SMN2MAPTALDH1A1LMNACYP4F2
SCHEMBL15391888 0.81 SMN1; SMN2 (0.60) SMN1; SMN2MAPTALDH1A1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2015-10-01 US disclosed
US-9067888-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2015-06-30 US disclosed
CN-102834380-B Inhibitors of protein kinases ASTRAZENECA 2015-04-01 CN disclosed
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-26 US disclosed
WO-2013171281-A1 HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS VIVALIS (FR) 2013-11-21 WO disclosed
US-8518948-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-27 US disclosed
EP-2545037-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2013-01-16 EP disclosed
CN-102834380-A Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH 2012-12-19 CN disclosed
US-20110224225-A1 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2011-09-15 US disclosed
WO-2011110612-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130345233-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 SMN1; SMN2 2779/4885MAPT 1266/4885ALDH1A1 2914/4885
US-20150272947-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK3 SMN1; SMN2 2779/4885MAPT 1266/4885ALDH1A1 2914/4885
US-20110224225-A1 Inhibitors of protein kinases CDK1, CDK2, CDK3 SMN1; SMN2 2779/4885MAPT 1266/4885ALDH1A1 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.